TTI — Thiogenesis Therapeutics Share Price
0.000.00%
Last trade - 00:00- CA$30.56m
- CA$26.42m
- 38
- 11
- 57
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.37 | ||
| Price to Tang. Book | 7.37 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -105.8% | ||
| Return on Equity | -108.88% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the obstacles facing thiol-based drugs, their short half-life, gastrointestinal (GI) side effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for MELAS, Leigh syndrome, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- May 3rd, 2018
- Public Since
- July 16th, 2019
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 46,306,890
- Address
- 4 King Street West, Suite 401, Toronto, M5H 1B6
- Web
- https://www.thiogenesis.com/
- Phone
- +1 6478467766
- Auditors
- MNP LLP
Upcoming Events for TTI
Q2 2025 Thiogenesis Therapeutics Corp Earnings Release
Thiogenesis Therapeutics Corp Annual Shareholders Meeting
Similar to TTI
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
FAQ
What is the Thiogenesis Therapeutics share price?
As of Today at 23:40 UTC, shares in Thiogenesis Therapeutics are trading at CA$0.66. This share price information is delayed by 15 minutes.
How has the Thiogenesis Therapeutics share price performed this year?
Shares in Thiogenesis Therapeutics last closed at CA$0.66 and the price had moved by -12% over the past 365 days. In terms of relative price strength the Thiogenesis Therapeutics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -21.76% over the past year.
What are the analyst and broker recommendations for Thiogenesis Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Thiogenesis Therapeutics dividend yield?
Thiogenesis Therapeutics does not currently pay a dividend.
Does Thiogenesis Therapeutics pay a dividend?
Thiogenesis Therapeutics does not currently pay a dividend.
When does Thiogenesis Therapeutics next pay dividends?
Thiogenesis Therapeutics does not currently pay a dividend.
How do I buy Thiogenesis Therapeutics shares?
To buy shares in Thiogenesis Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Thiogenesis Therapeutics?
As of the previous close price of CA$0.66, shares in Thiogenesis Therapeutics had a market capitalisation of CA$30.56m.
Where are Thiogenesis Therapeutics shares listed?
Here are the trading details for Thiogenesis Therapeutics:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: TTI
What kind of share is Thiogenesis Therapeutics?
Based on an overall assessment of its quality, value and momentum Thiogenesis Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Thiogenesis Therapeutics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Thiogenesis Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Thiogenesis Therapeutics. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +7.56%.
As of the last closing price of CA$0.66, shares in Thiogenesis Therapeutics were trading -0.68% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Thiogenesis Therapeutics PE Ratio?
The Thiogenesis Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Thiogenesis Therapeutics?
We do not have data on Thiogenesis Therapeutics' directors